55 research outputs found
Racial differences in smoking abstinence rates in a multicenter, randomized, open-label trial in the United States
Background: This study evaluates differences in smoking abstinence between white and minority smokers using pharmaceutical aids. Methods: This is an analysis of data from a multi-center, randomized, clinical trial conducted in the United States. Of the 1,684 subjects randomized to one of three medications (nicotine inhaler, bupropion, or a combination of both), 60% were women and 10% were minority races. Results: Factors associated with a decreased likelihood of smoking at 12 weeks were older age (OR = 0.971, p\u3c 0.0001), being married (OR = 0.678, p= 0.0029), using bupropion SR (OR = 0.480, pâ\u3câ0.0001), and using combination therapy (OR = 0.328, pâ\u3câ0.0001). Factors associated with an increased likelihood of smoking were higher tobacco dependence scores (OR = 1.244, p \u3c 0.0001), prior quit attempts (OR = 1.812, p=0.004), and being a minority (OR = 1.849, p=0.0083). Compared to white smokers, minority smokers were significantly older at time of study entry (46 vs. 42 years, p\u3c 0.0001), less likely to be married (35% vs. 59%, p\u3c 0.0001), older at smoking initiation (21 vs. 19 years of age, p\u3c 0.0001), and had a lower abstinence rate (16% vs. 26%, p=0.0065). Conclusion: Regardless of the treatment used, minority smokers in the US have lower smoking abstinence after treatment for tobacco dependence. Future research should focus on the improvement in treatment strategies for minority smokers
The impact of free trial acceptance on demand for alternative nicotine products: evidence from experimental auctions
A Class Of Weighted Log-Rank Tests For Survival Data When The Event Is Rare
this paper is sequential<E-386> data monitoring and repeated significance testing. This is particularly relevant<E-398> in many follow-up studies, including the PLCO trial. We are currently investigating<E-404> extensions of the modified G<E-211> #,#<E-220>
- âŠ